Payment overview · 2025
General Payments
$1,552.48
66 reported records · 17 companies
Healthcare provider profile · identity verified
Yi Wang, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · CITY OF INDUSTRY, CA · NPI 1427248319
Verified facts
What the public records show
CMS Open Payments records show Yi Wang, M.D. received $1,552.48 in general payments during 2025 across 66 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Entresto, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Rybelsus, Shingrix, Tymlos, Xifaxan, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 572 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 572 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Rybelsus by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Tymlos by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $287.10 | 18.5% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $255.54 | 16.5% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $211.46 | 13.6% | 12 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $144.20 | 9.3% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $110.10 | 7.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $81.96 | 5.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.27 | 5.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.14 | 4.8% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.02 | 4.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.25 | 3.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $38.43 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.93 | 2.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.50 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.44 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.56 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.65 | 1.0% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $14.93 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,552.48 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $255.54 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.52 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $144.65 | 6 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $144.20 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $110.10 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $88.70 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $87.22 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $81.96 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $78.27 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.37 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $71.02 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $50.03 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $31.50 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| Gel-One Cross-linked Hyaluronate Normalized: gel one cross linked hyaluronate |
Device | Zimmer Biomet Holdings, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 256 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 572 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 96 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 99 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 27 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
101 | 66 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
256 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
96 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
572 | 85 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
572 | 85 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
99 | 13 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1996 | 464 |
| Amlodipine Besylate | Amlodipine Besylate | 1492 | 315 |
| Losartan Potassium | Losartan Potassium | 1232 | 286 |
| Zolpidem Tartrate | Zolpidem Tartrate | 881 | 194 |
| Omeprazole | Omeprazole | 877 | 224 |
| Metformin Hcl | Metformin Hcl | 860 | 177 |
| Celecoxib | Celecoxib | 837 | 230 |
| Tamsulosin Hcl | Tamsulosin Hcl | 670 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 651 | 132 |
| Jardiance | Empagliflozin | 572 | 85 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 572 | 145 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 491 | 144 |
| Gabapentin | Gabapentin | 461 | 117 |
| Fluticasone Propionate | Fluticasone Propionate | 456 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 453 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 431 | 93 |
| Alendronate Sodium | Alendronate Sodium | 394 | 92 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 377 | 84 |
| Simvastatin | Simvastatin | 309 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 276 | 52 |
| Vascepa | Icosapent Ethyl | 274 | 50 |
| Ztlido | Lidocaine | 264 | 47 |
| Farxiga | Dapagliflozin Propanediol | 256 | 54 |
| Ketoconazole | Ketoconazole | 251 | 73 |
| Dexlansoprazole Dr | Dexlansoprazole | 250 | 45 |
| Donepezil Hcl | Donepezil Hcl | 248 | 46 |
| Januvia | Sitagliptin Phosphate | 244 | 40 |
| Azithromycin | Azithromycin | 238 | 178 |
| Hydrocortisone | Hydrocortisone | 238 | 79 |
| Allopurinol | Allopurinol | 233 | 47 |
| Linzess | Linaclotide | 228 | 47 |
| Ezetimibe | Ezetimibe | 226 | 50 |
| Icosapent Ethyl | Icosapent Ethyl | 217 | 54 |
| Azelastine Hcl | Azelastine Hcl | 214 | 48 |
| Finasteride | Finasteride | 202 | 39 |
| Famotidine | Famotidine | 192 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 189 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 189 | 34 |
| Cyclosporine | Cyclosporine | 183 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 167 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 166 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 38 |
| Memantine Hcl | Memantine Hcl | 158 | 34 |
| Montelukast Sodium | Montelukast Sodium | 153 | 27 |
| Atenolol | Atenolol | 151 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 24 |
| Glipizide | Glipizide | 144 | 32 |
| Lorazepam | Lorazepam | 144 | 22 |
| Nitroglycerin | Nitroglycerin | 142 | 34 |
| Valsartan | Valsartan | 142 | 28 |
| Sertraline Hcl | Sertraline Hcl | 140 | 28 |
| Carvedilol | Carvedilol | 137 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 22 |
| Ranolazine Er | Ranolazine | 135 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 25 |
| Lidocaine | Lidocaine | 134 | 25 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 134 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 104 |
| Eliquis | Apixaban | 125 | 21 |
| Myrbetriq | Mirabegron | 125 | 17 |
| Restasis | Cyclosporine | 120 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 119 | 103 |
| Xarelto | Rivaroxaban | 118 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 111 | 44 |
| Furosemide | Furosemide | 110 | 23 |
| Meloxicam | Meloxicam | 109 | 28 |
| Alprazolam | Alprazolam | 108 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 27 |
| Sucralfate | Sucralfate | 108 | 24 |
| Mirtazapine | Mirtazapine | 106 | 23 |
| Prolia | Denosumab | 101 | 66 |
| Rybelsus | Semaglutide | 99 | 13 |
| Temazepam | Temazepam | 99 | 17 |
| Amoxicillin | Amoxicillin | 98 | 87 |
| Dutasteride | Dutasteride | 98 | 24 |
| Mounjaro | Tirzepatide | 98 | 14 |
| Memantine Hcl Er | Memantine Hcl | 97 | 17 |
| Kerendia | Finerenone | 96 | 18 |
| Mupirocin | Mupirocin | 96 | 21 |
| Novolog Flexpen | Insulin Aspart | 96 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 91 | 15 |
| Ciclopirox | Ciclopirox | 87 | 24 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 85 | 15 |
| Febuxostat | Febuxostat | 82 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 81 | 17 |
| Creon | Lipase/Protease/Amylase | 79 | 14 |
| Trazodone Hcl | Trazodone Hcl | 78 | 18 |
| Glimepiride | Glimepiride | 77 | 14 |
| Pregabalin | Pregabalin | 77 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 76 | 14 |
| Colchicine | Colchicine | 76 | 22 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 76 | 18 |
| Lisinopril | Lisinopril | 71 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 70 | 19 |
| Gemfibrozil | Gemfibrozil | 69 | 14 |
| Clonidine Hcl | Clonidine Hcl | 68 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Benazepril Hcl | Benazepril Hcl | 64 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 64 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 60 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 12 |
| Meclizine Hcl | Meclizine Hcl | 54 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 11 |
| Irbesartan | Irbesartan | 52 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 51 | suppressed |
| Baclofen | Baclofen | 50 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 50 | suppressed |
| Entecavir | Entecavir | 50 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 49 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 13 |
| Terazosin Hcl | Terazosin Hcl | 48 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 47 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 46 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | suppressed |
| Nifedipine Er | Nifedipine | 46 | suppressed |
| Tradjenta | Linagliptin | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 36 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 44 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Xiidra | Lifitegrast | 44 | suppressed |
| Rivastigmine | Rivastigmine | 42 | suppressed |
| Gemtesa | Vibegron | 41 | 11 |
| Latanoprost | Latanoprost | 40 | 13 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Sotalol | Sotalol Hcl | 40 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 36 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 35 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 34 | 21 |
| Clobetasol Propionate | Clobetasol Propionate | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Prednisone | Prednisone | 32 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Ertapenem | Ertapenem Sodium | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 27 |
| Tymlos | Abaloparatide | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 15 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 30 | 20 |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Procto-Med Hc | Hydrocortisone | 29 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 28 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | 11 |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Naproxen | Naproxen | 21 | 14 |
| Prolensa | Bromfenac Sodium | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 13 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Airsupra | Albuterol Sulfate/Budesonide | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 11 |
| Nystatin | Nystatin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bromsite | Bromfenac Sodium | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,552.48 · 66 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, ENTRESTO, EVENITY, FARXIGA, GEMTESA, Gel-One Cross-linked Hyaluronate, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Tymlos, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error